GleamWall
中文EN

LPCN Lipocine Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1535955 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.4%
TTM net income YoY-70.4%
TTM EPS YoY-22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-269.1%
Net margin-249.2%
FCF margin—
EBITDA margin-267.5%

Returns

ROE-52.9%
ROA-47.5%
ROIC (approx.)-55.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio11.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio3.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.29M$190,099$119,397$1.15M$114,574$622,849$93,864$3.49M
R&D expense$2.07M$2.04M$2.76M$2.68M$2.71M$2.14M$1.06M$1.07M
SG&A expense$1.09M$990,956$1.20M$983,390$767,837$890,433$1.12M$873,055
Operating income-$868,525-$2.84M-$3.85M-$2.52M-$3.36M-$2.40M-$2.09M$1.55M
Pretax income-$666,192-$2.62M-$3.67M-$2.37M-$3.19M-$2.21M-$1.86M$1.78M
Income tax$0$200—$0$0$0$200$0
Net income-$666,192-$2.62M-$3.67M-$2.37M-$3.19M-$2.21M-$1.86M$1.78M
EBITDA-$853,878-$2.83M-$3.83M-$2.50M-$3.35M-$2.39M-$2.07M$1.56M
EPS (basic)-0.08-0.32-0.54—-0.59-0.41-0.35—
EPS (diluted)-0.08-0.32-0.54—-0.59-0.41-0.35—
Weighted avg. shares (diluted)8.24M8.22M6.80M—5.41M5.35M5.35M—
Balance sheet
Cash & equivalents$2.59M$4.98M$5.02M$5.21M$3.90M$6.04M$3.35M$6.21M
Short-term investments$18.86M$18.29M$19.71M$9.72M$11.23M$11.89M$16.36M$15.43M
Current assets$23.11M$23.74M$25.24M$16.88M$15.93M$18.42M$20.33M$22.32M
PP&E, net$60,184$74,831$89,479$104,293$119,274$133,397$149,505$165,075
Total assets$23.20M$23.84M$25.36M$17.01M$16.07M$18.58M$20.50M$22.51M
Current liabilities$2.03M$2.07M$2.53M$2.53M$1.93M$1.45M$1.30M$1.51M
Total liabilities$2.03M$2.07M$2.53M$2.53M$1.93M$1.45M$1.30M$1.51M
Shareholders' equity$21.16M$21.77M$22.83M$14.48M$14.14M$17.13M$19.20M$21.00M
Shares outstanding8.25M8.24M7.48M6.16M5.42M5.37M5.35M5.35M
Cash flow statement
Operating cash flow-$1.81M-$3.03M-$2.26M-$2.92M-$2.99M-$1.89M-$1.97M$1.70M
Capital expenditure———————$10,019
Free cash flow———————$1.69M
Investing cash flow-$577,630$1.48M-$9.90M$1.57M$701,449$4.50M-$882,073$761,058
Financing cash flow$0$1.51M$11.97M$2.65M$141,334——$0
Depreciation & amortization$14,647$14,648$14,814$14,981$14,123$16,108$15,570$15,571
Stock-based compensation$74,094$58,145$65,398$53,034$53,256$65,205$71,002$99,086

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.